Sophia Abene

16 cases of Salmonella Enteritidis across 10 states, including seven hospitalizations, are under investigation; antimicrobial resistance may complicate treatment.

Cocrystal Pharma to launch phase 1b study by year-end 2025, targeting prevention and treatment of viral gastroenteritis caused by norovirus.

41 cases of nongroupable N meningitidis conjunctivitis were identified at Joint Base San Antonio-Lackland, highlighting diagnostic, treatment, and surveillance implications for congregate living settings.

From COVID-19 antivirals to RSV, influenza, malaria, and gram-negative infections, new research highlights both advances and ongoing challenges in infectious disease prevention and treatment.

Up to 2 million people in low- and lower-middle-income countries may gain access to the long-acting PrEP option under a three-year, no-profit agreement.

The financing supports phase 3 evaluation of Sidiprev, a first-in-class, nonantibiotic therapy designed to prevent C difficile infections, a leading US health care–associated threat.

WHO and HRP highlight new research on HIV communication, STI priorities, and inclusive strategies to strengthen sexual health worldwide.

Single-center randomized trial shows lower infection rates and extended time to SARS-CoV-2 infection, though larger studies are needed to confirm findings.

Supported by phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.

In the DAN-RSV trial of 131,000 participants, RSVpreF lowered overall cardiorespiratory hospitalizations but showed no significant reduction in cardiovascular events.

Results from a Danish trial of more than 330,000 adults 65 years or older found high- and standard-dose influenza vaccines had similar effectiveness against influenza or pneumonia-related hospitalizations.

This week, expert insights highlighted progress in reducing C difficile with electronic hand hygiene monitoring, advancing HIV prevention with lenacapavir, updating COVID-19 vaccines for high-risk groups, and more.

Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.

CDC encourages travelers to take enhanced precautions, get vaccinated, and prevent mosquito bites in affected areas, with special warnings for pregnant individuals.

NYC officials confirm 113 cases and six deaths in Central Harlem cooling tower–linked outbreak; separate Bronx investigation underway after cases tied to hot water system.

Allergist and immunologist Juanita Mora, MD, urges vaccination, masking, and outreach to safeguard vulnerable communities.

A 9-month pilot study showed a 55% reduction in resident colonization with MRSA, VRE, and ESBL, but contamination of high-touch surfaces persisted in rooms of MDRO carriers.

Systematic review finds FMT and standardized microbiome products outperform antibiotics in efficacy and safety.

Regulators cite four new serious adverse event reports, halting US distribution while global access efforts continue.

This week, people with HIV are living longer on antiretroviral therapy but face elevated comorbidity risks, requiring tailored screening and multidisciplinary care as they age, and more.

New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.

STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.

A decade-long study finds the ratio independently predicts risk, with patients aged ≥30 facing higher progression rates.

First-in-class IL-15 agonist aims to address persistent post-COVID symptoms by enhancing immune clearance and restoring T cell memory.

ECDC warns climate shifts are driving longer mosquito seasons and expanding disease transmission, calling for stronger surveillance, vector control, and clinician preparedness.

Philippa Easterbrook, MD, MPH, FRCP, explains barriers in primary care, the promise of community models, and how simplified guidelines could expand access to treatment.

Morris County resident was infected despite no recent travel; risk to public remains low, officials say.

Julia Moore Vogel, PhD, says the LoCITT study aims to expand access through a fully remote design using CareEvolution’s MyDataHelps platform.

The renewed federal panel aims to improve vaccine oversight and restore public trust amid declining immunization rates and ongoing concerns about vaccine ingredients.

This week, predictive microbiome models for C difficile, synergistic antibiotic strategies for E faecalis, to pharmacy-led hepatitis C care, and more.